Monograph Details
|
|
Neoplasms
> Alkylating agents
|
|
ALKERAN FOR INJECTION |
| Manufacturer |
|
GlaxoSmithKline Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Nitrogen mustard derivative. |
| Generic Name |
|
Melphalan HCl 50mg/vial; pwd for IV infusion after reconstitution and dilution. |
| Also |
|
• ALKERAN
|
| Indications |
|
Palliative treatment of multiple myeloma when oral therapy is not appropriate. |
| Children |
|
Not recommended. |
| Adults |
|
Give by IV infusion over 15–20 minutes. 16mg/m2 every 2 weeks for a total of 4 doses, then at 4-week intervals. Continue treatment as hematological recovery permits. Renal insufficiency (BUN≥30mg/dL): consider reducing dose by 50%. |
| Contraindications |
|
Prior resistance to melphalan. |
| Precautions |
|
Prior irradiation or chemotherapy. Bone marrow suppression. Azotemia. Monitor platelets, hemoglobin, WBC and differential at start of therapy and prior to each course; discontinue if WBC <3,000cells/µL or platelets <100,000cells/µL. Moderate to severe renal impairment. Elderly. Pregnancy (Cat.D), nursing mothers: not recommended. |
| Interactions |
|
Radiotherapy potentiates antineoplastic effect. For IV: caution with cyclosporine, cisplatin, BCNU, nalidixic acid. |
| Adverse Reactions |
|
Bone marrow suppression, GI upset, hepatic dysfunction, anemia, blood dyscrasias, secondary malignancies (eg, nonlymphocytic leukemia), rash, alopecia, pulmonary fibrosis, interstitial pneumonitis, gonadal toxicity (amenorrhea, infertility); hypersensitivity reactions, cardiac arrest (rare). |
| How Supplied |
Tabs—50
Single-use vial—1 (w. diluent) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
